This R16 is headed by Dr. Benedict Albensi (NSU Pharm Sci) and is a 4-year, $616,000 grant funded by NINDS. The project will investigate the safety and efficacy of nilotinib (an FDA-approved chemotherapy drug) in a mouse model of AD, in the absence and presence of metabolic disease. Dr. Robison serves as co-investigator.